{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:55:16Z","timestamp":1780563316497,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jpba.2024.115996","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T15:23:32Z","timestamp":1706801012000},"page":"115996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Methamphetamine as the most common concomitant substance used with pregabalin misuse"],"prefix":"10.1016","volume":"241","author":[{"given":"Duygu Ye\u015fim","family":"OVAT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukiye","family":"ASLAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"KIRLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serap Annette","family":"AKG\u00dcR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.115996_bib1","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.euroneuro.2006.04.005","article-title":"Pregabalin: from molecule to medicine","volume":"16","author":"Kavoussi","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpba.2024.115996_bib2","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.115996_bib3","first-page":"164","article-title":"Ergenlik D\u00f6neminde Yeni Bir Tehdit: Pregabalin Suistimali","volume":"9","author":"TEKEL\u0130","year":"2019","journal-title":"\u0130zmir Dr. Beh\u00e7et Uz \u00c7ocuk Hastan. Derg."},{"key":"10.1016\/j.jpba.2024.115996_bib4","first-page":"200","article-title":"The attitudes of Turkish physicians in the treatment of fibromyalgia; is \u201cPregabalinophobia\u201d the new reality of pain medicine?","volume":"34","author":"Ketenci","year":"2022","journal-title":"J. Turkish Soc. Algol."},{"key":"10.1016\/j.jpba.2024.115996_bib5","unstructured":"Charles V. Preuss; Arun Kalava; Kevin C. King Prescription of Controlled Substances: Benefits and Risks - StatPearls - NCBI Bookshelf, Available at: \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537318\/\u3009, 2023."},{"key":"10.1016\/j.jpba.2024.115996_bib6","first-page":"177","article-title":"The pregabalin abuse in adolescent case that opioid using disorder \u00d6mer","volume":"9","author":"Karda\u015f","year":"2019","journal-title":"J. Contemp Med."},{"key":"10.1016\/j.jpba.2024.115996_bib7","unstructured":"World Health Organization, Critical Review Report: Pregabalin. Expert Committee on Drug Dependence Forty-First Meeting, Geneva, 2018."},{"key":"10.1016\/j.jpba.2024.115996_bib8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","article-title":"Pregabalin abuse and dependence in Germany: results from a database query","volume":"69","author":"Gahr","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.115996_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/appi.ajp.2010.09091269","article-title":"Pregabalin abuse, dependence, and withdrawal: a case report","volume":"167","author":"Grosshans","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpba.2024.115996_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpba.2024.115996_bib11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s00228-013-1578-5","article-title":"Pregabalin abuse among opiate addicted patients","volume":"69","author":"Grosshans","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.115996_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2014 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2024.115996_bib13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.4045\/tidsskr.10.0986","article-title":"Ja pregabalin kan misbrukes!","volume":"130","author":"Westin","year":"2010","journal-title":"Tidsskrift Den Norske legeforening"},{"key":"10.1016\/j.jpba.2024.115996_bib14","series-title":"Temel Adli Toksikoloji","article-title":"Adli Ama\u00e7l\u0131 Madde Testi Denetimli Serbestlik Uygulamas\u0131 ve Madde Testleri","author":"Akg\u00fcr","year":"2018"},{"key":"10.1016\/j.jpba.2024.115996_bib15","unstructured":"C. Apaydin, H. Kaplan, CEZA INFAZ SISTEMI VE DENETIMLI SERBESTLIK, 2019."},{"key":"10.1016\/j.jpba.2024.115996_bib16","unstructured":"Prime Ministry General Directorate of Legislation Development and Publication, T.C. Official Gazette Probation Services Regulation\u201d Available at: \u3008https:\/\/www.resmigazete.gov.tr\/eskiler\/2018\/02\/20180210-9.htm\u3009."},{"key":"10.1016\/j.jpba.2024.115996_bib17","unstructured":"Scientific Working Group for Forensic Toxicology (SWGTOX) Standard Practices for Method Validation in Forensic Toxicology, 2013, DOI 10.1093\/jat\/bkt054."},{"key":"10.1016\/j.jpba.2024.115996_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40263-017-0467-3","article-title":"Pregabalin use among users of illicit drugs: a cross-sectional survey in Southern Germany","volume":"31","author":"Snellgrove","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpba.2024.115996_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/hup.2486","article-title":"Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas","volume":"30","author":"Martinotti","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jpba.2024.115996_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3389\/fpsyt.2019.01022","article-title":"Pregabalin abuse in combination with other drugs: monitoring among methadone patients","volume":"0","author":"Lancia","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jpba.2024.115996_bib21","article-title":"The pregabalin abuse in adolescent case that opioid using disorder","author":"Karda\u015f","year":"2019","journal-title":"J. Contemp. Med."},{"key":"10.1016\/j.jpba.2024.115996_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case\u2013control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.jpba.2024.115996_bib23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/add.14412","article-title":"Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings","volume":"114","author":"Cairns","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jpba.2024.115996_bib24","article-title":"Pregabalin qualitative detection in Turkish forensic cases between 2017 to 2018","author":"Teker","year":"2023","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.jpba.2024.115996_bib25","first-page":"672","article-title":"For pain: potential unintended consequences","volume":"100","author":"Goodman","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jpba.2024.115996_bib26","unstructured":"European Monitoring Center for Drugs and Drug Addiction (EMCDDA). European Drug Report 2022, 2022."},{"key":"10.1016\/j.jpba.2024.115996_bib27","unstructured":"Republic of T\u00fcrkiye Ministry of Interior, Turkish Drug Report Trend and Developments, 2023."},{"key":"10.1016\/j.jpba.2024.115996_bib28","unstructured":"EWDTS. European Workplace Drug Testing Society European Guidelines for Workplace Drug Testing in Urine, 2015, Version2.0."},{"key":"10.1016\/j.jpba.2024.115996_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0379-0738(01)00445-5","article-title":"Workplace drug testing in Europe","volume":"121","author":"Verstraete","year":"2001","journal-title":"Forensic Sci. Int."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:39:13Z","timestamp":1760002753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":29,"alternative-id":["S0731708524000360"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.115996","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methamphetamine as the most common concomitant substance used with pregabalin misuse","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.115996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115996"}}